Outlook Therapeutics, Inc.
Business
Outlook Therapeutics is a biopharmaceutical company that develops ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab approved in the European Union and United Kingdom for treating wet age-related macular degeneration, with a biologics license application under FDA review for the United States. The company manufactures its product in the United States and commercializes it directly in approved markets, with a strategic distribution partnership in Europe. Outlook also holds legacy biosimilar development rights and a joint venture license for the greater China market.
Summary from 10-K filed 2025-12-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Revenues, net | 1 | — | — | — | — | |
| Cost of revenues | 1 | — | — | — | — | |
| Gross profit | 57,205 | — | — | — | — | |
| Research and development | 27 | 42 | 26 | 42 | 39 | |
| Selling, general and administrative | 40 | 30 | — | — | — | |
| Loss from operations | −67 | −72 | −53 | −63 | −52 | |
| Loss on equity method investment | 141,007 | 100,742 | 10,998 | 48,730 | 46,340 | |
| Interest income | −89,738 | −906,150 | −971,480 | — | — | |
| Interest expense | 283,128 | 3 | 2 | 1 | 936,127 | |
| Loss from change in fair value of promissory notes | 6 | 2 | 4 | 882,903 | — | |
| Warrant related expenses (Note 10) | — | 37 | — | — | — | |
| Warrant inducement expenses (Note 10) | 34 | — | — | — | — | |
| Gain from change in fair value of warrant liability | −43 | −39 | −50,919 | −465,780 | 452,146 | |
| Loss before income taxes | −64 | −75 | −59 | −66 | −53 | |
| Income tax (benefit) expense | −2 | 2,800 | 2,800 | 2,800 | 2,000 | |
| Net loss | −62 | −75 | −59 | −66 | −53 | |
| Net loss per share of common stock, basic (in dollars per share) | −1.79 | −4.06 | −4.72 | −0.31 | −0.35 | |
| Net loss per share of common stock, diluted (in dollars per share) | −1.79 | −4.06 | −4.72 | −0.31 | −0.35 | |
| Weighted average shares outstanding, basic (in shares) | 35 | 19 | 13 | 212 | 153 | |
| Weighted average shares outstanding, diluted (in shares) | 35 | 19 | 13 | 212 | 153 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 15 | 23 | 17 | 14 | |
| Accounts receivable | 1 | — | — | — | — | |
| Inventory | 3 | — | — | — | — | |
| Prepaid expenses and other current assets | 4 | 12 | 8 | 10 | 7 | |
| Total current assets | 17 | 27 | 31 | 28 | 22 | |
| Operating lease right-of-use assets, net | 225,508 | 274,645 | 26,172 | 70,360 | 111,429 | |
| Equity method investment | 552,183 | 693,190 | 793,932 | 804,930 | 853,660 | |
| Other assets | 417,523 | 439,283 | 501,299 | 132,015 | 174,590 | |
| Total assets | 19 | 29 | 32 | 29 | 23 | |
| Current portion of unsecured convertible promissory note | 30 | 29 | 36 | 11 | 904,200 | |
| Current portion of operating lease liabilities | 58,897 | 50,907 | — | 26,995 | 42,854 | |
| Accounts payable | 10 | 8 | 7 | 3 | 2 | |
| Accrued expenses | 5 | 3 | 3 | 3 | 2 | |
| Income taxes payable | 302,000 | 2 | 2 | 2 | 2 | |
| Total current liabilities | 46 | 43 | 47 | 20 | 7 | |
| Operating lease liabilities | 188,801 | 246,922 | — | — | 26,995 | |
| Warrant liability | 5 | 59 | 6,219 | 57,138 | 522,918 | |
| Total liabilities | 51 | 102 | 47 | 20 | 18 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding | — | — | — | — | — | |
| Common stock, par value $0.01 per share; 260,000,000 shares authorized; 53,887,233 and 23,905,635 shares issued and outstanding at September 30, 2025 and September 30, 2024, respectively | 538,873 | 239,057 | 130,128 | 2 | 2 | |
| Additional paid-in capital | 573 | 470 | 453 | 415 | 346 | |
| Accumulated deficit | −606 | −543 | −468 | −409 | −343 | |
| Total stockholders' deficit | −32 | −73 | −14 | 9 | 5 | |
| Total liabilities and stockholders' deficit | 19 | 29 | 32 | 29 | 23 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Amortization | 117,052 | 113,859 | 44,188 | 204,694 | 262,140 | |
| Non-cash interest expense | — | 3 | 3 | 2 | 893,886 | |
| Stock-based compensation | 9 | 5 | 6 | 8 | 5 | |
| Accounts receivable | −1 | — | — | — | — | |
| Inventory | −3 | — | — | — | — | |
| Prepaid expenses and other current assets | 8 | −5 | 3 | −3 | −2 | |
| Other assets | −95,247 | −5,900 | −208,203 | — | — | |
| Operating lease liabilities | −50,131 | 3,413 | −26,995 | −42,854 | −150,346 | |
| Accounts payable | 2 | 1 | 3 | 1 | −198,469 | |
| Accrued expenses | 2 | 491,728 | −711,661 | 156,141 | −5 | |
| Income taxes payable | −2 | — | — | — | — | |
| Net cash used in operating activities | −52 | −69 | −43 | −57 | −54 | |
| Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs | 25 | 60 | 30 | 62 | 46 | |
| Proceeds from exercise of common stock warrants | 23 | — | — | 188,100 | 4 | |
| Proceeds from debt | 33 | — | 30 | 10 | 10 | |
| Payments of finance lease obligations | — | −4,267 | −11,751 | −26,464 | −29,778 | |
| Repayment of debt | −36 | — | −10 | −12 | −50,285 | |
| Net cash provided by financing activities | 45 | 60 | 49 | 60 | 56 | |
| Net (decrease) increase in cash and cash equivalents | −7 | −8 | 6 | 3 | 2 | |
| Cash paid for interest | — | 475,000 | 1 | 2 | 46,239 | |
| Convertible promissory note converted into common stock | 3 | 11 | 25,000 | — | — | |
| Recognition of warrant liability | — | 98 | — | — | — | |
| Fair value of common stock warrants exercised reclassified from warrant liability to equity | 13 | — | — | — | — | |
| Common stock and warrant issuance costs in accounts payable and accrued expenses | 924,271 | — | — | — | — | |
| Reclassification of deferred offering costs against ATM proceeds | 49,092 | — | 141,600 | — | — | |
| Right-of-use asset and lease liability recognized for new operating lease liabilities | — | 294,416 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Outlook Therapeutics, Inc.'s CIK number?
Outlook Therapeutics, Inc.'s SEC CIK number is 0001649989 (1649989). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Outlook Therapeutics, Inc.'s SEC filings?
All of Outlook Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Outlook Therapeutics, Inc. last report earnings?
Outlook Therapeutics, Inc. (OTLK) most recently filed an earnings 8-K with the SEC on May 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-062865). This is Outlook Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Outlook Therapeutics, Inc.'s most recent earnings 8-K?
Outlook Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 18, 2026 under accession 0001104659-26-062865. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Outlook Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →